Christopher Ma
0000-0002-4698-9948
27 papers found
Refreshing results…
Reduction in surgical stoma rates in Crohn's disease: a population‐based time trend analysis
Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease
Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort
A Rare Cause of Chronic Abdominal Pain
76 Surgical Resection Rates for Crohn's Disease Are Decreasing: A Population-Based Time Trend Analysis
Mo1092 Cost-Utility Analysis Shows Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis
Mo1832 Validation of Administrative Data for Capturing Crohn's Disease Patients Requiring Surgical Bowel Resection
Mo1887 Early Initiation of Anti-TNF Therapy Does Not Reduce Colectomy or Hospitalization Rates in Ulcerative Colitis: A Retrospective Cohort Study
Su1800 Fecal Immunochemical Testing and Fecal Calprotectin Predict Mucosal Healing in Inflammatory Bowel Disease: A Prospect Study
Anti-TNF Therapy Within 2 Years of Crohnʼs Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort Study
Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study
Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis
General Internal Medicine
Recurrent Fevers After Infliximab Therapy for Ulcerative Colitis
Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response:
Sa1212 IBD Patients Are Frequently Non-Adherent With Scheduled Induction and Maintenance Infliximab Infusions
Inflammatory bowel disease patients are frequently nonadherent to scheduled induction and maintenance infliximab therapy: A Canadian cohort study
Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: A real life cohort study
Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease
Su1397 Outpatients With Ulcerative Colitis Being Treated With Adalimumab and Infliximab Have Similar Rates of Loss of Response
Missing publications? Search for publications with a matching author name.